Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age

NCT07406360 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07406360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07406360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Recruiting
Start date
May 11, 2026
Completion date
July 20, 2028
Enrollment
1,209 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

measles, measles-mumps-rubella+chickenpox vaccine